Trial Profile
A trial conducted under a compassionate program for COVID-19 patients
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs COVID-19 infection therapeutics Charite University of Medicine Berlin/Pluristem Therapeutics (Primary)
- Indications COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- Sponsors Pluri
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 14 May 2020 According to a Pluristem Therapeutics media release, 7 patients have completed a 28-day follow up period.
- 14 May 2020 Results presented in the Pluristem Therapeutics Media Release.